How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

998 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. A Comparison of the Hormonal Profile of Early Androgenetic Alopecia in Men With the Phenotypic Equivalent of Polycystic Ovarian Syndrome in Women. Full Text available with Trip Pro

A Comparison of the Hormonal Profile of Early Androgenetic Alopecia in Men With the Phenotypic Equivalent of Polycystic Ovarian Syndrome in Women. Early androgenetic alopecia (AGA) is patterned hair loss occurring before age 30 years. Early AGA in men is frequently reported as the phenotypic equivalent of polycystic ovarian syndrome (PCOS) in women, which carries the risk of developing obesity, metabolic syndrome, and cardiovascular diseases. Very few studies have been conducted to evaluate (...) . Men who had any established endocrine disorder, diabetes mellitus, or cardiovascular disease and those who took any oral medication or hormonal treatment for hair loss were excluded from the study. The serum concentrations of total testosterone, sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, fasting plasma glucose, and insulin levels were measured. Insulin resistance (IR) and free androgen index

2016 JAMA dermatology (Chicago, Ill.)

122. Androgenetic Alopecia. Modelling Progression and regrowth. Full Text available with Trip Pro

Hair Follicle Humans androgenic balding female pattern baldness male 2016 03 29 2016 4 11 6 0 2016 4 12 6 0 2018 2 1 6 0 ppublish 27061176 10.1111/exd.13029 (...) Androgenetic Alopecia. Modelling Progression and regrowth. 27061176 2018 01 31 2018 01 31 1600-0625 25 6 2016 06 Experimental dermatology Exp. Dermatol. Androgenetic alopecia. Modelling progression and regrowth. 424-5 10.1111/exd.13029 Sinclair Rodney R Department of Dermatology, University of Melbourne, Epworth Hospital, Melbourne, Vic., Australia. eng Journal Article Comment Denmark Exp Dermatol 9301549 0906-6705 IM Exp Dermatol. 2016 Jun;25(6):482-4 26782302 Alopecia Disease Progression Hair

2016 Experimental Dermatology

123. Factors affecting the severity of central centrifugal cicatricial alopecia. (Abstract)

Factors affecting the severity of central centrifugal cicatricial alopecia. Central centrifugal cicatricial alopecia (CCCA) is a type of scarring hair loss primarily seen in African-American women. The risk factors that affect the severity of disease remain unclear.This study was designed to elucidate risk factors that may be associated with severity of CCCA.A cross-sectional survey study was conducted. Women with biopsy-confirmed CCCA responded to a questionnaire and were grouped according (...) was noted in 16 subjects (42.1%). The average duration of hair loss was 5.7 years in early-stage disease and 10.1 years in advanced-stage disease. There was a positive correlation between duration of hair loss and degree of hair loss (Spearman's correlation 0.471, P = 0.003).This study reports on data sourced from patients with biopsy-confirmed CCCA and examines the relationships between various factors and severity of CCCA. The findings demonstrate that duration of hair loss is positively associated

2016 International Journal of Dermatology

124. Hunting the genes in male pattern alopecia: How important are they, how close are we, and what will they tell us? Full Text available with Trip Pro

Hunting the genes in male pattern alopecia: How important are they, how close are we, and what will they tell us? Androgenetic alopecia (AGA) is a highly heritable condition, and the most common form of hair loss in men. The phenotype is characterized by an androgen-dependent, progressive loss of hair from the scalp, which may commence during puberty. Up to 80% of European men experience some degree of androgen-dependent hair loss during their lifetime. Current treatment options for AGA have (...) limited efficacy, and improved understanding of the underlying biological causes is required to facilitate novel therapeutic approaches. To date, molecular genetic studies have implicated 12 genomic regions in AGA and identified a number of candidate genes. The latter include those encoding the androgen receptor (AR), the histone deacetylases (HDAC) 4 and 9, and the WNT molecule WNT10A. However, the majority of contributing genetic risk factors still await identification. This review describes

2016 Experimental Dermatology

125. Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia Full Text available with Trip Pro

Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia After the approval of dutastride for androgenic alopecia (AGA) in 2009, Korean authority required a post-marketing surveillance to obtain further data on its safety profile.The objective was to monitor adverse events (AEs) of dutasteride 0.5 mg in Korean AGA male patients in a clinical practice environment.Open label, multi-center, non-interventional observational study was done

2016 Annals of dermatology

126. Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 49 Years (Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year Exclusion Criteria: History (...) Sponsor: Allergan Information provided by (Responsible Party): Allergan Study Details Study Description Go to Brief Summary: This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients with androgenetic alopecia (AGA). Condition or disease Intervention/treatment Phase Alopecia Alopecia, Androgenetic Baldness Drug: Bimatoprost Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 53 participants

2016 Clinical Trials

127. STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia

: Other Study ID Numbers: 003-A-II First Posted: July 21, 2015 Last Update Posted: March 7, 2018 Last Verified: March 2018 Keywords provided by Kerastem Technologies, LLC: Female Pattern Baldness Male Pattern Baldness Genetic Alopecia Androgenic Alopecia Hair Loss Additional relevant MeSH terms: Layout table for MeSH terms Alopecia Alopecia Areata Hypotrichosis Hair Diseases Skin Diseases Pathological Conditions, Anatomical (...) information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Males with a diagnosis of Alopecia Androgenetica Females with a diagnosis of Alopecia Androgenetica Males with hair loss consistent with Grades III, IIIA, III-Vertex, IV, IV-A, based on Norwood-Hamilton Scale (Figure 1) Females with hair loss consistent with Grades I-3, I-4, II-1, II-2 based

2015 Clinical Trials

128. A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

conditioner is optional for subjects who do not use conditioner Exclusion Criteria: Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia Scalp hair loss on the treatment area, due to disease, injury, or medical therapy Males who are sexually active and have a partner who is capable of becoming pregnant, neither of whom have had surgery to become sterilized, that are not using a highly effective method of birth control and are not willing to use a highly effective method of birth (...) cell carcinoma, squamous cell carcinoma) located anywhere on the body History of surgical correction of hair loss on the scalp Previous exposure to SM04554 Use of blood thinners (e.g., Coumadin, Plavix, Lovenox, and aspirin >81mg); low dose aspirin (e.g., ≤81 mg) is allowable Use of any products or devices clinically proven to promote scalp hair growth (e.g., finasteride or minoxidil) within 24 weeks prior to study start Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone

2015 Clinical Trials

129. Adipose-derived SVF for Treatment of Alopecia

subject. Stromal Vascular Fraction (SVF) will be disassociated within the GID SVF-2 from the autologous adipose tissue to be injected into a small (approximately 2x2cm) area of the scalp in men or women with androgenic alopecia. Device: GID SVF-2 Comparison of the number of hairs before and after treatment of autologous adipose-derived SVF as a percentage increase or decrease in growth. Outcome Measures Go to Primary Outcome Measures : Incidence of Treatment-emergent Adverse Events (Safety) [ Time (...) : Treatment Official Title: Adipose-derived Stromal Vascular Fraction (SVF) Injections to Stimulate Hair Regrowth for Androgenetic Alopecia Actual Study Start Date : July 20, 2016 Actual Primary Completion Date : January 22, 2017 Actual Study Completion Date : January 22, 2017 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: SVF Injection Liposuction of a small amount of adipose tissue will be taken from each

2015 Clinical Trials

130. LEO 124249 Ointment in the Treatment of Alopecia Areata

) investigator, affecting a minimum of 30% scalp area at Visit 1 (Screening) and Visit 2 (Day 1, baseline). Minimum 6 month duration of hair loss at Visit 1 (Screening). No upper limit time limit. Subject must accept to not cut hair in the treated scalp areas during the trial. Exclusion Criteria: Females who are pregnant or are breast feeding. Current signs of spontaneous hair regrowth. Diffuse type alopecia areata. Co-existing moderate to severe androgenic alopecia (Norwood-Hamilton stage IV-VI and Ludwig (...) : This clinical trial attempts to investigate the efficacy and safety of LEO 124249 ointment in the treatment of alopecia areata and the molecular disease mechanism and biomarkers. Condition or disease Intervention/treatment Phase Alopecia Areata Drug: LEO 124249 Other: Vehicle Phase 2 Detailed Description: The objectives of this clinical trial are to compare the efficacy of twice-daily topical LEO 124249 30 mg/g ointment with LEO 124249 ointment vehicle for 12 weeks in the treatment of hair loss in subjects

2015 Clinical Trials

131. Conditions simulating androgenetic alopecia. (Abstract)

Conditions simulating androgenetic alopecia. Androgenetic alopecia is a common form of hair loss, characterized by a progressive hair follicular miniaturization, caused by androgen hormones on a genetically susceptible hair follicle, in androgenic-dependent areas. Characteristic phenotype of androgenetic alopecia is also observed in many other hair disorders. These disorders are androgenetic-like diseases that cause many differential diagnosis or therapeutic error problems. The objective

2015 Journal of the European Academy of Dermatology and Venereology

132. The association of androgenetic alopecia and insulin resistance is independent of hyperandrogenemia: A case-control study. (Abstract)

The association of androgenetic alopecia and insulin resistance is independent of hyperandrogenemia: A case-control study. Androgenetic alopecia (AGA) occurs due to the effect of androgens and genetic predisposition. The association between hyperandrogenism and insulin resistance (IR) has been clearly documented. In recent years there have been reports supporting the presence of IR in AGA. The study aimed to investigate the presence of IR in women with AGA and discern whether

2015 Australasian Journal of Dermatology

133. Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: An update of what we now know. (Abstract)

Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: An update of what we now know. The role of genetic predisposition and the influence of sex steroid hormones are indisputable to the pathogenesis of male androgenetic alopecia (MAGA). The role of sex steroid hormones in female pattern hair loss (FPHL) is less known. A good knowledge of the pathophysiology underlying MAGA and FPHL empowers the clinician to confidently counsel patients and make (...) informed therapeutic decisions. Vigorous research in recent years has provided greater insight into the role of genetics and sex steroids in physiological hair growth and cycling, as well as in hair follicle miniaturization, the histological hallmark of MAGA and FPHL. In the present review article directed towards clinicians, we discuss the current understanding of the role of androgens and oestrogens, as well as genetic associations with MAGA and FPHL. We also briefly discuss the interpretation

2011 Australasian Journal of Dermatology

134. Androgen excess: Investigations and management. (Abstract)

Androgen excess: Investigations and management. Androgen excess (AE) is a key feature of polycystic ovary syndrome (PCOS) and results in, or contributes to, the clinical phenotype of these patients. Although AE will contribute to the ovulatory and menstrual dysfunction of these patients, the most recognizable sign of AE includes hirsutism, acne, and androgenic alopecia or female pattern hair loss (FPHL). Evaluation includes not only scoring facial and body terminal hair growth using (...) the modified Ferriman-Gallwey method but also recording and possibly scoring acne and alopecia. Moreover, assessment of biochemical hyperandrogenism is necessary, particularly in patients with unclear or absent hirsutism, and will include assessing total and free testosterone (T), and possibly dehydroepiandrosterone sulfate (DHEAS) and androstenedione, although these latter contribute limitedly to the diagnosis. Assessment of T requires use of the highest quality assays available, generally

2016 Best practice & research. Clinical obstetrics & gynaecology

135. What do urologists think patients need to know when starting on androgen deprivation therapy? The perspective from Canada versus countries with lower gross domestic product Full Text available with Trip Pro

patients about: osteoporosis, loss of muscle mass, weight gain, fatigue/sleep disturbance, relationship changes, cognitive changes, and loss of body hair. Infertility was the only side effect more often disclosed by urologists in low GDP counties. Recommended management strategies for hot flashes are more likely to be pharmaceutical in Canada, and behavioral in low GDP countries. Management strategies for gynecomastia are emphasized more in low GDP countries. Physical exercise is endorsed consistently (...) What do urologists think patients need to know when starting on androgen deprivation therapy? The perspective from Canada versus countries with lower gross domestic product Androgen deprivation therapy (ADT) side effects are numerous and negatively impact prostate cancer patients' quality of life. There is considerable discrepancy though among Canadian urologists regarding what ADT side effects and side effect management strategies. Little is known about global differences in ADT patient

2016 Translational andrology and urology

136. Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

) and HER2 negative breast cancer by IHC and /or fluorescence in situ hybridization (FISH) Androgen receptor positive (AR+) Defined as >= 50% nuclear AR staining by immunohistochemistry (IHC) in either the primary or metastatic lesion NOTE: Research testing of AR status is available at City of Hope Pathology Resolution of grade 2 and above toxicities of most recent therapy except for stable sensory neuropathy (=< grade 2) and alopecia Female (childbearing potential): use an adequate method of birth (...) Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2016 Clinical Trials

137. The Androgen Receptor Antagonizes Wnt/β-Catenin Signaling in Epidermal Stem Cells. Full Text available with Trip Pro

The Androgen Receptor Antagonizes Wnt/β-Catenin Signaling in Epidermal Stem Cells. Activation of Wnt/β-catenin signaling in adult mouse epidermis leads to expansion of the stem cell compartment and redirects keratinocytes in the interfollicular epidermis and sebaceous glands (SGs) to differentiate along the hair follicle (HF) lineages. Here we demonstrate that during epidermal development and homeostasis there is reciprocal activation of the androgen receptor (AR) and β-catenin in cells (...) of the HF bulb. AR activation reduced β-catenin-dependent transcription, blocked β-catenin-induced induction of HF growth, and prevented β-catenin-mediated conversion of SGs into HFs. Conversely, AR inhibition enhanced the effects of β-catenin activation, promoting HF proliferation and differentiation, culminating in the formation of benign HF tumors and a complete loss of SG identity. We conclude that AR signaling has a key role in epidermal stem cell fate selection by modulating responses to β-catenin

2015 Journal of Investigative Dermatology

138. Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia Full Text available with Trip Pro

Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia Androgenetic alopecia (AGA) is the most common form of hair loss. Clinically observed hair loss is due to the continuous miniaturization of affected hair follicles. Genetic factors and androgenic factors especially dihydrotestosterone (DHT), which is a testosterone tissue metabolite, play major roles in the pathogenesis of AGA. However, expert opinions about the usefulness of DHT (...) in the diagnosis of this type of alopecia are divided.To evaluate the usefulness of DHT level in patients with androgenetic alopecia compared with the control group.The study comprised 49 subjects: 19 women and 9 men with androgenetic alopecia. The control group consisted of 17 healthy women and 4 men without hair loss.Increased serum concentrations of DHT were observed in patients with androgenetic alopecia (17 women, 5 men), but also in the control group. The differences in mean values of DHT were

2014 Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

139. A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males

to 60 Years (Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Male with a diagnosis of Androgenetic Alopecia according to the Guidelines of the American Academy of Dermatology Experiencing active hair loss within the last 12 months. In general good health Norwood-Hamilton classification of 3, 3A, 3V, 4, 4A, or 5 Skin Type I, II, III or IV on the Fitzpatrick Skin Type Scale Between 20 and 60 years of age at the time of enrollment Willing to have a dot (...) of this protocol is to demonstrate that the intended users of the X5 HairLaser can safely and effectively perform self-use application by following written instructions. Condition or disease Intervention/treatment Phase Androgenetic Alopecia Device: X5 HairLaser Device: X5 Hair Laser Sham Device Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Intervention Model: Parallel Assignment Primary Purpose: Treatment Official Title: A Randomized, Double

2014 Clinical Trials

140. Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia

. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Men between the ages 18-65. Disease Stage: Norwood Hamilton IIIa-IV. Length of time with disease < 10 years. Exclusion Criteria: Must not have other concurrent hair disease. Have not used any oral anti androgen (Finasteride or Dutasteride) in the past six months. If so, a washout (...) for additonal information Responsible Party: Jerry Shapiro, Clinical Professor, Vancouver General Hospital ClinicalTrials.gov Identifier: Other Study ID Numbers: H13-03501 First Posted: June 3, 2014 Last Update Posted: June 3, 2014 Last Verified: May 2014 Additional relevant MeSH terms: Layout table for MeSH terms Alopecia Alopecia Areata Hypotrichosis Hair Diseases Skin Diseases Pathological Conditions, Anatomical Minoxidil Antihypertensive Agents Vasodilator Agents

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>